Anwesha Ray Senapati

@akhilrk1989 @TheIACH Thank you Akhil!

@AnweshaRayS @TheIACH Congratulations @AnweshaRayS

🙂 Moving the Needle in KMT2A Rearranged Pediatric B-Cell Acute Lymphoblastic Leukemia: Newer agents and novel approaches | Published in Clinical Hematology International share.google/oCG3jPf09xhxE0… #leusm @TheIACH

@jtgeorgy @TheIACH Thanks Josh! It was great meeting you during ASCO.

@AnweshaRayS @TheIACH Many congratulations @AnweshaRayS. Great review!

@ManasDasMD @TheIACH Thanks Manas!

@AnweshaRayS @TheIACH Amazing paper, Dr. Ray. Keep up the good work. Best wishes.

@VergheseRenjith @MVijayaran @TheIACH Thanks so much Dr. Verghese.

@AnweshaRayS @MVijayaran @TheIACH Heartiest congratulations Anwesha

🙂 Very Happy to share this comprehensive review on AML, from an @MDAndersonNews perspective, discussing all that is new and exciting in the field 🩸 @DrHKantarjian ➡️ Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges @AcsCancer acsjournals.onlinelibrary.wiley.com/doi/full/10.10…

🙏🙂 Very happy to share our manuscript on a granular analysis of a large cohort of Secondary Type AML with respect to contemporary therapies: ➡️ Clinico-genomic classification of AML ontogeny: Clinical secondary (CS), Genomic Secondary (GS) and Pure De novo (DN) AML🧬 ➡️ GS-AML defined by only MDS type mutations have outcomes comparable to pure DN-AML with Ven based Rx💊 ➡️ GS-AML is a heterogenous group depending on presence of MDS related muts or CTG🧬 ➡️ Adverse CTG remain relevant in AML treated with LIT+Ven, even with recent ELN2024 risk stratification @AjHematology @MDAndersonNews @DrHKantarjian onlinelibrary.wiley.com/doi/full/10.10…

#ASH24 starts this week! Excited to attend the annual scientific extravaganza and interact with friends, colleagues, collaborators and industry at San Diego. Happy to present the following studies from @MDAndersonNews at #ASH24 ➡️ Check them out if you are interested in AML/ALL @DrHKantarjian

Dar-ting at CD38 in T-cell leukemias ow.ly/Glz450Uckpm #lymphoidneoplasia

➡️ Check out our commentary in @BloodJournal on the Delphinus Study (with Daratumumab based combination) in R/R ALL @MDAndersonNews @ Elias Jabbour 🎯 Dar-ting at CD38 in T-cell leukemias ashpublications.org/blood/article/…

🙏🏽What a profound loss for a Nation! A visionary and philanthropist who placed the country and people before himself and spearheaded @TataCompanies to become a global giant. His active involvement in improving cancer care services in India deserves utmost respect. His legacy will continue to live as his lifework continues to inspire millions. RIP! Om Shanti.

➡️ Check our our latest paper @LeukemiaJnl on HyperCVAD+Nel+PegAsp w/wo VEN frontline Rx in adult pts with T-ALL/LBL ✅️mFU of 5yrs= med PFS and OS not reached (5yr rates: 64% & 66%) ✅️ VEN cohorts trend to fare better vs original cohorts: 2yr PFS: 88% vs 65%; OS 88% vs 74% nature.com/articles/s4137… Happy to co-lead this paper with @fravandi1

@mithunap11 @jayastuMD @OffCMCVellore @aiims_newdelhi @TataMemorial @NutanJoshi27 @akhilrk1989 @royjpalatty Thanks for your kind words!

Thank your warm hospitality and being such gracious hosts @jayastuMD @AnweshaRayS. You have both made this trip and #SOHO2024 so much more memorable for all of us. To more such nights reminiscing about @OffCMCVellore @aiims_newdelhi and @TataMemorial!!

🧑🏽‍⚕️The recent horrific incident in West Bengal, India on a resident physician has sent shock waves across India and world: Safety of healthcare providers, women and all citizens is of foremost importance and one of the primary duties of the State. No compromise and No excuses! ✅The wrath of the people is justified and peaceful protests are the strength of a democracy. reuters.com/world/india/in… 🧵 Thread 1/7 @IMAIndiaOrg @AIIMSRDA @FAIMA_INDIA_ @timesofindia

👉🏽 Check out our recent paper on the outcomes of N/D patients with AML having WBC >100x10e9 at presentation ✅63% had FLT3 mut ✅8 week mortality of 13%: all in pts >65 years ✅Age>65, LDH>2000, high lactates, adverse CTG prognostic for OS @FadiHaddad_MD @DrHKantarjian @TapKadia #leusm Outcomes of Patients With Newly Diagnosed AML and Hyperleukocytosis | JCO Oncology Practice ascopubs.org/doi/10.1200/OP…

➡️ Happy to share this patient centric article pub in @ConquerMag on the progress in Leukemia therapy over the last 2 decades. @MDAndersonNews @DrHKantarjian Revolutionizing Leukemia Care: A Journey of Breakthroughs & Hope - Conquer: the journey informed conquer-magazine.com/issues/2024/vo…

🙏🏼3 years today since I joined the Dept of Leukemia @MDAndersonNews. Amazing experience to work & learn amongst the best & being able to do the best for our pateints. Thankful to my dept & chair @DrHKantarjian, my mentors, colleagues, friends & patients. faculty.mdanderson.org/profiles/jayas…

➡️ Check out our latest paper: - >60 y/o👴🏽pts with AML who had AlloSCT after Clad/LDAC/Ven alt with HMA-Ven (Clinical trial @TapKadia) had promsing survival outcomes✅️ - Superior RFS, lower CIR than >60 y/o pts👵🏻who had SCT after Int Rx @MDAndersonNews acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn…

🙏🏼 Its always a feeling of pride to work in @MDAndersonNews as we strive the best for our patients who come to us with hope & the promise of getting the best care. The Leukemia dept chaired by @DrHKantarjian is at the forefront of leukemia Rx & research. youtu.be/Swlt5Vz5O2k?si…